The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs for a low, fixed copayment no higher than $2 for a month’s supply per drug.  
 
"Providing low, fixed copayments for common generic drugs, as CMS proposed, could help increase medication adherence and improve health outcomes," AHA wrote. "This model would standardize cost sharing for certain drugs for beneficiaries with Medicare Part D enrolled in a participating plan and their health care providers." 
 
The AHA provided recommendations for how to account for shortages in the approved drug list and for public rulemaking to update the drug list annually, as well as feedback on potential quality measures for the model. Additional details on the request for information can be found on the M2DL webpage. Comments on the model are due to the Centers for Medicare & Medicaid Services today and must be submitted through a survey portal.

Related News Articles

Headline
The Department of Health and Human Services Jan. 17 announced 15 Medicare Part D drugs selected for the latest round of price negotiations. Negotiations will…
Headline
The Medicare Payment Advisory Commission today voted to recommend that Congress update Medicare payment rates for hospital inpatient and outpatient services by…
Headline
The Centers for Medicare & Medicaid Services Jan. 10 proposed a 4.3% payment increase to Medicare Advantage plans for calendar year 2026, amounting to…
Headline
Prices for the top 25 brand-name Medicare Part D drugs have increased by an average of 98% since entering the market, according to a report released Jan. 9 by…
Headline
The AHA Dec. 17 released its Health Care Plan Accountability Update, covering the latest developments in Medicare Advantage, legislation and regulation of…
Headline
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023.…